ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Enrollment Completed in Phase II Clinical Study of KN026 Combined with KN046
January 13, 2022Alphamab Oncology (stock code: 9966.HK) announced that the phase II clinical study of KN026 (HER2 bispecific antibody) combined with KN046 (PD-L1/CTLA-4 bispecific antibody) (KN026-203)... -
Posters Highlighting clinical data of KN026 presented at SABCS 2021
December 10, 2021lphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. (stock code: 1093.HK) jointly announced that two posters highlighting data from two clinical studies of the anti-HER2 bispecific antibody... -
IND Application for Phase III Clinical Study of Anti-HER2 Bispecific Antibody KN026 was Officially Accepted by CDE
October 21, 2021Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. (stock code: 1093.HK) jointly announced IND application for a phase III clinical study of recombinant humanized anti-HER2 bispecific antibody KN026...
Pharma Sources Insight January 2025
